NCM
ARTV

Nantahala Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Nantahala Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Buy
+300,000
New +$2.73M 0.1% 124

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Nantahala Capital Management's ARTV Position: Q2 2026 in Review

Nantahala Capital Management opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 300,000 shares worth $2.91M. The stake represents 0.1% of the portfolio and ranks #124 among its holdings.

72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Nantahala Capital Management held 300,000 shares of Artiva Biotherapeutics worth $2.91M as of Q2 2026.
  • Artiva Biotherapeutics was a new Nantahala Capital Management position in Q2 2026.
  • Artiva Biotherapeutics made up 0.1% of Nantahala Capital Management's portfolio in Q2 2026, its #124 holding.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.